A Phase 3 interventional study of Suzetrigine and Placebo in Total Knee Replacement Surgery and Post-operative Pain, sponsored by Icahn School of Medicine at Mount Sinai. Recruiting at 1 site in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-04-23.
Sponsored by Icahn School of Medicine at Mount Sinai · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing suzetrigine in Pain, Postoperative — 17 open to participants now, 17 under way, 4 of them phase 3. suzetrigine · Pain, Postoperative.
Among the 18 studies testing suzetrigine in Pain, Postoperative, this one has the largest planned enrollment, is one of 15 that started in 2026, is one of 4 in phase 3, reaches primary completion later than 3 of the 16 other live ones, and was the 7th registered.
5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.
Browse Pain, Postoperative studies →17 of the 18 studies testing suzetrigine in Pain, Postoperative are open now, in 1 country. Recruiting first, the newest first:
University of California, San Diego · Sites in United States
Ages 18+
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18–85
University of California, San Diego · Sites in United States
Ages 18+
University of Minnesota · Sites in United States
Ages 18+
Beth Israel Deaconess Medical Center · Sites in United States
Ages 18+
By country, each count listing its studies:
suzetrigine: first FDA approval 2025 (JOURNAVX). What it is approved for, and how studies give it, is on its page →
Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2025; this study’s year is marked. 15 started in 2026.
This study's planned enrollment of 235 is above the median of 75 across 4,859 interventional studies indexed under Pain, Postoperative.
Median enrollment 115 across the 18 interventional studies. Of the 1 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 18 has an industry lead sponsor. The 10 most frequent:
Icahn School of Medicine at Mount Sinai is the lead sponsor of 776 studies on the registry; 175 are open to participants now.
Of its 125 completed or terminated interventional studies of FDA-regulated products, 83 (66%) have results posted.
14 studies in Pain, Postoperative by Icahn School of Medicine at Mount Sinai: 3 open now, 3 under way, 2 of them phase 3. Of 11 finished, 7 (64%) have results posted.
Among the 14 studies in Pain, Postoperative by Icahn School of Medicine at Mount Sinai, this one has the largest planned enrollment, is one of 2 that started in 2026, is one of 4 in phase 3, and was the 14th registered.
Icahn School of Medicine at Mount Sinai’s Pain, Postoperative studies by the year they started, since 2011.
9 of the studies testing suzetrigine in Pain, Postoperative that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07539623Phase 3Icahn School of Medicine at Mount SinaiSuzetrigine-enhanced MultimOdal Opioid-sparing THerapy in Cardiac and Bariatric SURGery | 2026-12-22 |
| NCT07548385Phase 3Icahn School of Medicine at Mount SinaiSuzetrigine for Treatment and Reduction of Intense Discomfort After knEe Replacement PAIN | 2027-02-23 |
| NCT07839715Phase 3Vanderbilt University Medical CenterSuzetrigine Post DIEP | 2027-08 |
| NCT07355166University of California, Los AngelesSuzetrigine Versus Usual-care Opioids for Postop Pain in Sports | 2027-01 |
| NCT07821931Stanford UniversitySuzetrigine in Tonsillectomy for Opioid-sparing Pain Management | 2027-06 |
Add all 9 to your calendar (.ics) → With an account.
Among the 18 studies testing suzetrigine in Pain, Postoperative, from their registry updates:
Among Icahn School of Medicine at Mount Sinai’s 14 in Pain, Postoperative:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a prospective, randomized study. The purpose of this study is to evaluate if the addition of Suzetrigine, a new pain medication, to well established peri-operative pain regimen used for total knee replacement surgery will effect pain control.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
To be eligible to participate in this study, an individual must meet all of the following criteria:
Exclusion Criteria:
Any individual who meets any of the following criteria will be excluded from participation in this study:
to administration of Suzetrigine:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive 100 mg loading dose (2 pills) of Suzetrigine medication pre-operatively, then 50 mg dose (1 pill) of Suzetrigine every 12 hours for total of 5 days.
Drug: Suzetrigine
Participants will receive 2 pills that are made to look like the Suzetrigine pill to take per-operatively, then 1 pill every 12 hours for a total of 5 days.
Drug: Placebo
Suzetrigine is a new pain medication that works by inhibiting sodium channels (NAV 1.8) on pain nerves in the peripheral nervous system. By inhibiting this sodium channel on peripheral nerves it blocks pain signals from reaching the spinal cord and brain, decreasing pain.
Matching placebo
Opioid Consumption
Total amount of opioid consumption required post-operatively.
Time frame: 5 days
Visual analog pain scale
Participants perceived post-operative pain measured daily using the visual analog scale for pain. Total score is 0 to 10, higher score indicates more pain.
Time frame: 5 days
Plan to share: No — We are not sharing IPD to protect participant privacy, maintaining study integrity, and respecting intellectual property
No publications or documents are linked to this record.
Start is estimated for Apr 2026; primary completion for Feb 2027, 10 months later.
Of 124 non-industry phase 3 interventional studies under Pain, Postoperative, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 10 months is below that.
Counting every sponsor, half of 167 studies reached it within 17 months; a quarter within 8 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Suzetrigine
Icahn School of Medicine at Mount Sinai →